Mansur, AhmetGündüz, Ayten2025-10-242025-10-2420252980-0463https://doi.org/10.71133/anatphar.1630540https://hdl.handle.net/20.500.12899/2038Pseudomonas aeruginosa is the main Pseudomonas species causing hospital infections. Ceftazidime-avibactam (CZA) is a new beta-lactam/beta-lactamase inhibitor combination effective against carbapenem-resistant P. aeruginosa isolates. The aim of this study was to evaluate the in vitro activity of CZA against carbapenem-resistant P. aeruginosa isolates. In hospitalized patient culture samples, 190 isolates that were evaluated as significant growth and identified as P. aeruginosa with the Vitek 2 Compact automated system (BioMérieux, France) and determined as imipenem resistant (? 8 mg/L) and meropenem resistant (? 16 mg/L)with the same system were included in the study. 88% (167/190) of P. aeruginosa strains were isolated from patients in intensive care units and 78% (148/190) from respiratory tract samples. CZA activity was studied with disk diffusion test (10-4 µg disk) and zone diameterseninfo:eu-repo/semantics/openAccessBacteriologyBakteriyolojiArticle10.71133/anatphar.1630540414852